GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Gross Profit

NRXS (Neuraxis) Gross Profit : $1.98 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Gross Profit?

Neuraxis's gross profit for the three months ended in Jun. 2024 was $0.54 Mil. Neuraxis's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was $1.98 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Neuraxis's gross profit for the three months ended in Jun. 2024 was $0.54 Mil. Neuraxis's Revenue for the three months ended in Jun. 2024 was $0.61 Mil. Therefore, Neuraxis's Gross Margin % for the quarter that ended in Jun. 2024 was 87.91%.

Neuraxis had a gross margin of 87.91% for the quarter that ended in Jun. 2024 => Durable competitive advantage

During the past 4 years, the highest Gross Margin % of Neuraxis was 88.94%. The lowest was 75.08%. And the median was 85.26%.


Neuraxis Gross Profit Historical Data

The historical data trend for Neuraxis's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Gross Profit Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross Profit
1.45 2.25 2.39 2.16

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.41 0.46 0.57 0.54

Competitive Comparison of Neuraxis's Gross Profit

For the Biotechnology subindustry, Neuraxis's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's Gross Profit distribution charts can be found below:

* The bar in red indicates where Neuraxis's Gross Profit falls into.



Neuraxis Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Neuraxis's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=2.46 - 0.303
=2.16

Neuraxis's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=0.612 - 0.074
=0.54

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.98 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Neuraxis's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.54 / 0.612
=87.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Neuraxis  (AMEX:NRXS) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Neuraxis had a gross margin of 87.91% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Neuraxis Gross Profit Related Terms

Thank you for viewing the detailed overview of Neuraxis's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042